Savara (SVRA) Tops Q2 EPS by 8c

Savara (NASDAQ: SVRA) reported Q2 EPS of ($0.16), $0.08 better than the analyst estimate of ($0.24).

“With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year,” said Rob Neville, Chief Executive Officer, Savara. “Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure the potential efficacy and safety of Molgradex to treat aPAP.”

For earnings history and earnings-related data on Savara (SVRA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• Sysco adds two directors, targets AI-driven cost savings of $100M